Low grade dysplasia

Reading File

Asking for Preferences

Finding Sources

Searching PubMed

"Barrett's esophagus" AND "low grade dysplasia" AND management

Reading File

Finding Sources

Reading File

Loading Image

Finding Sources

Reading Article

PMID: 38763697

Here is a thorough overview of low-grade dysplasia (LGD) in Barrett's esophagus, drawn from multiple authoritative GI textbooks and the latest AGA guideline.

Low-Grade Dysplasia in Barrett's Esophagus

What is it?

Low-grade dysplasia (LGD) is one of the histological grades along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's esophagus. Dysplasia is the histological expression of the genetic and epigenetic changes that favor neoplastic cell growth - specifically the accumulation of mutations (beginning with p53 inactivation) that alter cell morphology in a way pathologists can recognize under the microscope.

Barrett metaplasia is classified into four grades:

No dysplasia
Indefinite for dysplasia
Low-grade dysplasia (LGD)
High-grade dysplasia (HGD)

Yamada's Textbook of Gastroenterology, 7e, p. 946

Histopathology

The biopsy image below shows LGD (at 11 o'clock) alongside high-grade dysplasia (center). In LGD, cellular abnormalities are present but less pronounced than HGD - nuclear enlargement, crowding, and loss of normal polarity are seen but confined to the lower portions of the crypts.

Fig. 47.4 - Sleisenger and Fordtran's GI and Liver Disease

The Diagnostic Challenge

LGD is notoriously difficult to diagnose reliably:

Histological changes of LGD can closely mimic reactive/regenerative changes from reflux esophagitis.
Interobserver agreement among pathologists is poor (<50%) for LGD.
A landmark Netherlands study found community pathologists diagnosed LGD, but expert GI pathologists confirmed it in only 15% of cases. However, in those confirmed cases, the cumulative risk of neoplastic progression reached 85% at 9 years.
By contrast, an American study of 210 LGD patients found progression of only 0.4% per year, with no association between diagnostic consensus and progression.
Because of this diagnostic variability, expert GI pathologist confirmation is mandatory before acting on an LGD diagnosis.
Yamada's Textbook of Gastroenterology, 7e, p. 946; Sleisenger and Fordtran's GI and Liver Disease

Natural History & Risk of Progression

Finding	Annual Progression Risk
Non-dysplastic Barrett esophagus	~0.25% per year to adenocarcinoma
Development of LGD from non-dysplastic BE	~4.3% per year
LGD to adenocarcinoma	Variable: 0.4% (US data) to very high in confirmed cases
High-grade dysplasia to adenocarcinoma	~6% per year

The overall annual risk of progression from Barrett esophagus to esophageal adenocarcinoma is 0.29%, and the risk is significantly higher in patients who already have LGD at baseline.

Mulholland and Greenfield's Surgery, 7e, p. 2066; Sleisenger and Fordtran's

Management

Step 1 - Confirm the diagnosis

Expert GI pathologist review is mandatory. If the diagnosis is "indefinite for dysplasia," give PPI therapy at 60-80 mg for 3 months and rebiopsy - severe inflammation makes histological interpretation unreliable.

Step 2 - Endoscopic evaluation

Any patient with dysplasia requires careful high-definition white-light endoscopy (HD-WLE). The Seattle biopsy protocol (4-quadrant biopsies every 1-2 cm) is standard but has real sampling limitations. Any visible mucosal irregularity, nodule, or ulceration should be removed by EMR (endoscopic mucosal resection) for histological staging before ablation.

Step 3 - Treatment decision

Endoscopic Eradication Therapy (EET) is the procedure of choice for LGD once the diagnosis is confirmed.

Option	Role in LGD
Radiofrequency ablation (RFA)	Preferred ablation modality; can eradicate nearly 100% of LGD. Recommended to ablate all remaining Barrett metaplasia after any visible lesions are resected.
EMR	For any visible lesions; provides staging information; now considered mandatory before ablation in most guidelines
Surveillance endoscopy (every 6-12 months)	Acceptable alternative for patients who place higher value on avoiding procedure-related harms; shared decision making required
Nissen fundoplication	A reasonable alternative in selected patients - evidence shows LGD reverts to non-dysplastic intestinal metaplasia after fundoplication in most cases
Esophagectomy	Reserved for rare cases where EET fails; not recommended as primary treatment

The 2024 AGA Clinical Practice Guideline (Rubenstein et al., Gastroenterology 2024) made a conditional recommendation in favor of EET in BE with LGD. Importantly, patients who place higher value on avoiding potential harms (esophageal stricture ~5.6%, bleeding ~1%, perforation ~0.6%) could reasonably choose endoscopic surveillance instead - shared decision making is central.

The 2025 AGA Surveillance Guideline (PMID: 41125322) further refines surveillance intervals for Barrett's esophagus.

EET Complications (RFA ± EMR)

From a systematic review of 9,200 patients:

Esophageal stricture: 5.6%
Bleeding: 1%
Perforation: 0.6%
Overall serious adverse events: 8.8%
Risk is significantly higher when RFA is combined with EMR (relative risk 4.4)
Sleisenger and Fordtran's GI and Liver Disease

Key Points Summary

LGD diagnosis requires expert pathologist confirmation due to high rate of overdiagnosis.
Once confirmed, LGD carries a meaningfully elevated cancer risk compared to non-dysplastic Barrett esophagus.
EET (RFA ± EMR) is the preferred treatment for confirmed LGD - AGA 2024 gives a conditional recommendation in its favor.
Surveillance endoscopy every 6-12 months is a reasonable alternative for patients who prefer it, through shared decision making.
All residual Barrett metaplasia should be ablated after resection of visible lesions to reduce metachronous neoplasia.
PPI therapy is maintained for acid suppression/chemoprevention throughout management.

This is a shared conversation. Sign in to Orris to start your own chat.